November 25, 2016 - By Ruchi Gupta
In a analysts note sent to clients and investors on Friday, 25 November, SunTrust Robinson Humphrey has decreased Juno Therapeutics (NASDAQ:JUNO) stock to a Hold and has set an estimated 12-month TP at $25.00. JUNO’s old rating was Buy.
Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 6 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 67% are positive. $73 is the highest target while $30 is the lowest. The $47.10 average target is 104.69% above today’s ($23.01) stock price. Juno Therapeutics Inc has been the topic of 20 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The company was initiated on Wednesday, November 18 by Goldman Sachs. Raymond James initiated the shares of JUNO in a report on Thursday, June 2 with “Outperform” rating. As per Tuesday, December 15, the company rating was upgraded by Standpoint Research. The firm has “Outperform” rating by FBR Capital given on Friday, July 8. Standpoint Research downgraded Juno Therapeutics Inc (NASDAQ:JUNO) on Thursday, October 29 to “Hold” rating. FBR Capital downgraded Juno Therapeutics Inc (NASDAQ:JUNO) on Wednesday, November 23 to “Mkt Perform” rating. The firm earned “Buy” rating on Thursday, February 25 by Citigroup. The firm has “Equal-Weight” rating by Barclays Capital given on Wednesday, July 6. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) has “Buy” rating given on Friday, August 5 by Maxim Group. The firm has “Outperform” rating by FBR Capital given on Tuesday, August 18.
The stock increased 1.99% or $0.45 during the last trading session, hitting $23.01. About 3.81M shares traded hands or 93.40% up from the average. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 49.28% since April 22, 2016 and is downtrending. It has underperformed by 54.69% the S&P500.
Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on March, 6. They expect $-0.66 EPS, down 22.22% or $0.12 from last year’s $-0.54 per share. After $-0.58 actual EPS reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts 13.79% negative EPS growth.
Insitutional Activity: The institutional sentiment increased to 1.4 in Q2 2016. Its up 0.06, from 1.34 in 2016Q1. The ratio increased, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Checchi Capital Advisers Limited Liability Company holds 162 shares or 0% of its portfolio. Moreover, Verition Fund Management Limited Liability Corporation has 0.03% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 6,883 shares. Arrowpoint Asset Mgmt Ltd Liability holds 526,717 shares or 0.41% of its portfolio. Alps Advisors, a Colorado-based fund reported 145,751 shares. X Management Ltd Liability Corporation, a New York-based fund reported 230 shares. Invesco Ltd accumulated 0% or 7,222 shares. American Grp holds 1,602 shares or 0% of its portfolio. Springbok Mngmt Limited Liability Corp last reported 500 shares in the company. Bamco New York holds 100,525 shares or 0.02% of its portfolio. Moreover, Geode Limited Liability Company has 0.01% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 497,300 shares. California Public Employees Retirement last reported 79,500 shares in the company. Raymond James holds 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 5,839 shares. Vident Invest Advisory Ltd Co owns 15,776 shares or 0.09% of their US portfolio. Jpmorgan Chase & last reported 0% of its portfolio in the stock. Dekabank Deutsche Girozentrale has 0.03% invested in the company for 60,000 shares.
Juno Therapeutics, Inc. is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The company has a market cap of $1.84 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
More recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fool.com which released: “Why Juno Therapeutics Inc Plummeted Today” on November 23, 2016. Also Marketwatch.com published the news titled: “UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient …” on November 23, 2016. Fool.com‘s news article titled: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” with publication date: November 03, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ruchi Gupta